About
Opsona developed drugs targeting the human immune system for autoimmune and inflammatory diseases, solid organ transplantation, and oncology before ceasing operations in 2019.
Explore Opsona's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.